[Recent developments in antipsychotic medication].
The development of new neuroleptics aims to reduce unwanted extrapyramidal motor side effects as well as the non-response rate, and to achieve a greater effect on negative symptoms. Preferential binding of neuroleptics to D2-receptors in the limbic system, as well as the combination of dopamine D2- and serotonin S2-antagonism proved to be effective. A potent D2-S2-antagonism as was realized with positive results in risperidone serves as a model for a whole class of new neuroleptics.
Möller
H J
HJ
Psychiatrische Klinik, Klinikum Innenstadt, München.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D018967:Risperidone
Neuere Entwicklungen in der antipsychotischen Medikation.